Hannah Robinson
Clinical Operations Director
I have a background in paediatric nursing and have worked in research at Oxford Vaccine Group since 2008.
I supervise and support the clinical teams and make sure the UK clinical trials are run safely, effectively and efficiently from a clinical perspective. With other senior members of the group I make sure our processes are up to date and work well. A large part of my role is looking at the feasibility of OVG's planned research and when and how it can be delivered.
Recent publications
Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.
Journal article
Paganotti Vicentine M. et al, (2026), BMJ Open, 16
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
Journal article
El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27
Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.
Journal article
Zivanovic N. et al, (2023), Clin Transl Med, 13
Salmonella Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort.
Journal article
Hanumunthadu B. et al, (2023), BMJ Open, 13
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet